Amgen shares plummet 5.8% marking largest single-day decline since November 12.

Amgen shares plummet 5.8% marking largest single-day decline since November 12.

Amgen Inc. (NASDAQ: AMGN) saw a significant drop in its stock price, with shares falling by 5.8% to $272.64 on June 19, 2025, marking the largest single-day decline since November 12, 2024. The company reported mid-stage data from its experimental weight-loss drug, MariTide, which showed that people started on a low dose achieved comparable weight loss to those on higher doses while experiencing milder side effects. However, the trial also reported a high rate of vomiting, with nearly 90% of patients experiencing it at the highest tested dose [1].

The company's stock has been volatile recently, with several institutional investors adjusting their positions. Nomura Holdings Inc. bought 10,778 shares during the fourth quarter, while RMB Capital Management LLC reduced its holdings by 5.1%. Bridgewater Associates LP increased its holdings by 421.1%, and several other investors also made significant changes to their positions [2].

Amgen's stock has been influenced by several factors, including clinical trial results, earnings forecasts, and investor sentiment. The company is expected to post earnings of $19.15 per share for FY2025, according to William Blair's estimates [3]. Despite the recent decline, the stock has seen an overall increase of 5.2% year-to-date, with the latest price action driven by mid-stage trial data [4].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3SQ1CA:0-amgen-falls-company-reports-mid-stage-data-from-experimental-weight-loss-drug/
[2] https://www.marketbeat.com/stocks/NASDAQ/AMGN/news/
[3] https://www.marketbeat.com/stocks/NASDAQ/AMGN/news/
[4] https://www.marketbeat.com/stocks/NASDAQ/AMGN/news/